Recently, our study showed that combination of dasatinib and gemcitabine exerts anti-proliferative effects by decreasing the expression of ALDH1A1 in pancreatic cancer MIA PaCa-2 cells with acquired resistance to gemcitabine [17]. This evidence concerns the gene ALDH1A1 and pancreatic neoplasm.